📇 Rhumatologue · CLICHY CEDEX · (92) · Hospitalier

M GEOFFREY ROSSI

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
38 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
136 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 CLICHY CEDEX (92)HospitalierRPPS 10101180643

🇫🇷 Publications académiques françaises (8)

✨ Génération du profil synthétique IA en cours…

Publications académiques en France

Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.

Short versus long-course antibiotic therapy for pyogenic liver abscess: an emulated target trial
2026
Article

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease

Arthritis & rheumatology (Hoboken, N.J.) · 2018

📚 240 citations🎯 RCR 12.50Top 2% NIH

Lire l'abstract Crossref ↓

Interstitial lung disease (ILD) is an increasingly recognized complication of rheumatoid arthritis (RA) and is associated with significant morbidity and mortality. In addition, approximately one‐third of patients have subclinical disease with varying degrees of functional impairment. Although risk factors for RA‐related ILD are well established (e.g., older age, male sex, ever smoking, and seropositivity for rheumatoid factor and anti–cyclic citrullinated peptide), little is known about optimal disease assessment, treatment, and monitoring, particularly in patients with progressive disease. Patients with RA‐related ILD are also at high risk of infection and drug toxicity, which, along with comorbidities, complicates further treatment decision‐making. There are distinct histopathologic patterns of RA‐related ILD with different clinical phenotypes, natural histories, and prognoses. Of these, the usual interstitial pneumonia (UIP) subtype of RA‐related ILD shares a number of clinical and histopathologic features with idiopathic pulmonary fibrosis, the most common and severe of the idiopathic interstitial pneumonias, suggesting the existence of common mechanistic pathways and possibly therapeutic targets. There remain substantial gaps in our knowledge of RA‐related ILD. Concerted multinational efforts by expert centers has the potential to elucidate the basic mechanisms underlying RA‐related UIP and other subtypes of RA‐related ILD and facilitate the development of more efficacious and safer drugs.

Drug-induced interstitial lung disease

The European respiratory journal · 2022

📚 117 citations🎯 RCR 11.63Top 2% NIH🔓 Open Access

Lire l'abstract Crossref ↓

Interstitial lung disease (ILD) secondary to drug-induced lung injury is an increasingly common cause of morbidity and mortality. The number of drugs associated with the development of ILD continues to rise, mainly due to the use of novel monoclonal antibodies and biologicals for neoplastic and rheumatological diseases, and includes, among others, chemotherapeutics, molecular targeting agents, immune checkpoint inhibitors, antibiotics, antiarrhythmics and conventional or biological disease-modifying antirheumatic drugs. Drug-induced ILD (DI-ILD) manifests with a variety of clinical patterns, ranging from mild respiratory symptoms to rapidly progressive respiratory failure and death. In most cases, there are no pathognomonic clinical, laboratory, radiological or pathological features and the diagnosis of DI-ILD is suspected in the presence of exposure to a drug known to cause lung toxicity and after exclusion of alternative causes of ILD. Early identification and permanent discontinuation of the culprit drug are the cornerstones of treatment with systemic glucocorticoids being used in patients with disabling or progressive disease. However, for certain drugs, such as checkpoint inhibitors, the frequency of lung toxicity is such that mitigation strategies are put in place to prevent this complication, and occurrence of DI-ILD is not necessarily synonymous with permanent drug discontinuation, particularly in the absence of valid therapeutic alternatives.

Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia

Science translational medicine · 2021

📚 62 citations🎯 RCR 3.43Top 13% NIH🔓 Open Access

Lire l'abstract Crossref ↓

Rituximab-resistant memory B cells and newly engaged naive B cells join to fuel subsequent autoimmune responses in patients with relapsing ITP.

Cookies & analyse de trafic

M GEOFFREY ROSSI

Pourquoi vous devez consulter ce praticien

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (38) — classées par pathologie

Transversal22

Essai clinique3

Lupus3

Revue générale2

Vascularites2

Anti-IL-171

Biothérapies non-anti-TNF1

Case report / série1

Corticothérapie1

Pédiatrie1

Revue / méta-analyse1

SAPL1

Partager cette fiche